Aggressive and indolent B-cell malignancies—diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)—are converging on a shared trajectory: risk-adapted frontline intensification paired with a shift away from chemotherapy toward antibody-based and cellular immunotherapies. In DLBCL, Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new frontline standard, leveraging CD79b-targeted antibody-drug conjugate biology alongside CD20-directed rituximab. Simultaneously, CD20×CD3 bispecific T-cell engagers (epcoritamab, glofitamab) and CD19-targeted agents (tafasitamab, often combined with golcadomide) are advancing from relapsed/refractory settings into earlier lines, reflecting a broader strategy of engaging T cells directly against malignant B cells rather than relying solely on cytotoxic chemotherapy. This is complemented by molecular subtype-tailored strategies and single-cell RNA sequencing efforts that dissect tumor heterogeneity and resistance mechanisms (e.g., monocyte-mediated suppression), pointing toward biomarker-driven treatment selection and real-world implementation challenges as these regimens move from trials into routine oncology practice.
In MCL, the field is undergoing a parallel de-escalation/escalation duality: BTK inhibitors (notably ibrutinib) are now core components of frontline therapy, increasingly displacing autologous stem cell transplantation except in high-risk subsets defined by MIPI and Ki-67 stratification or TP53-mutant biology, where targeted triplet regimens are being explored. This reflects a broader oncology theme—matching treatment intensity to biologically defined risk rather than uniform chemo-transplant paradigms, with rituximab maintenance persisting as a backbone across risk groups.
Cutting across both diseases is a maturing safety and manufacturing discourse for immune-engaging therapies. Pharmacovigilance analysis of FDA adverse event data reveals a disproportionate atrial fibrillation signal specifically tied to bispecific T-cell engagers (epcoritamab, mosunetuzumab), mechanistically linked to cytokine release, underscoring the need for cardiac monitoring as these agents proliferate across earlier treatment lines. In parallel, allogeneic ("off-the-shelf") CAR T-cell platforms are being engineered via CRISPR, TALEN, transposon, and surface-modification strategies to overcome alloreactivity and immune rejection, aiming to solve manufacturing scalability barriers that limit autologous cell therapies—though regulatory hurdles remain, and application is expanding beyond hematologic malignancies toward solid tumors. Together, these threads depict a field pivoting from cytotoxic combination chemotherapy toward engineered, target-specific immunotherapies, tempered by emerging toxicity signals and the practical hurdles of scaling next-generation cell products.